![](https://conferences.medicom-publishers.com/wp-content/uploads/2024/05/Brugts-portrait-square.jpg)
The findings have sparked discussions about the integration of such technologies into standard care, signalling a potential shift in heart failure management strategies. Medicom interviewed Dr Brugts to share the consideration of remote haemodynamic monitoring for patients with chronic heart failure.
Could you give us an overview of the key findings from MONITOR-HF that you presented at the Heart Failure Congress?
“I presented results from a subgroup analysis of the Monitor-HF trial, which tested the consistency of pulmonary pressure monitoring's treatment effect across several clinical endpoints like quality of life, heart failure events, mortality, and pulmonary artery pressure reductions [3]. We found that the treatment effect was consistent across all subgroups and clinical endpoints. There was no clinically relevant heterogeneity, meaning no specific subgroup of patients benefited more or less.”
Based on your research, how do you see remote monitoring technologies evolving in the near future?
"The heart failure community faces a great challenge with high morbidity and mortality. Remote monitoring is promising for reducing hospitalisations by delivering care outside the hospital. The evidence for pulmonary artery monitoring is robust, with trials like CHAMPION and GUIDE, and several real-world studies confirming its benefits [4,5]. In the coming years, I expect the technology to evolve, integrating into clinical pathways and health records, supported by e-health, AI, and algorithms. Involving patients in self-management through apps could further enhance efficiency and efficacy."
The results showed significant improvements in KCCQ overall summary score. What impact does this have on patients' day-to-day activities and overall health management?
"Monitor-HF had quality of life as a primary endpoint, showing significant improvements both short-term and long-term. Patients feel better and more confident with remote monitoring and personalised care. By monitoring and intervening on haemodynamic congestion early, even before symptoms appear, we provide reassurance and better management for patients."
Did you observe any safety signals about the CardioMEMS HF System or complications?
"The CardioMEMS HF system was safe and durable. In MONITOR-HF, we reported 2.3% procedure-related complications, comparable with other trials and right heart catheterisation. It's a low-risk procedure through the femoral vein. We also reported 2 sensor failures over the long term, about 1%, demonstrating high durability. Overall, the technology is safe with low complication rates."
- Brugts JJ, et al. The consistency of the treatment benefit of remote hemodynamic monitoring in chronic heart failure: a predefined subgroup analysis of the randomised clinical trial MONITOR-HF. Late breaking clinical trials I, Heart Failure 2024, 11–14 May, Lisbon, Portugal.
- Clephas PRD, et al. Eur Heart J. 2024 May 11:ehae323.
- Brugts JJ, et al; Lancet. 2023;401(10394):2113-2123.
- Abraham WT, et al. Lancet. 2016;387(10017):453-61.
- Lindenfeld J, et al. Lancet. 2021;398(10304):991-1001.
Copyright ©2024 Medicom Medical Publishers
Posted on
Previous Article
« Preventive PCI of vulnerable intracoronary plaque leads to favourable outcomes Next Article
HFA 2024 Highlights Podcast »
« Preventive PCI of vulnerable intracoronary plaque leads to favourable outcomes Next Article
HFA 2024 Highlights Podcast »
Table of Contents: HFA 2024
Featured articles
Meet the Trialist: Innovating cardiac monitoring with MONITOR-HF
Trials: Other
Individualised diuretic titration in acute HF without a physician
Intravenous iron deficiency treatment improves exercise capacity in patients with HFpEF
CD34+ stem cells promote reverse cardiac remodelling after acute MI
Registries
Sex-specific outcomes and resource utilisation after HF hospitalisation
Application of guideline-directed medical therapy in patients with HFrEF in the Netherlands
Devices
PAP-guided management system appears safe in patients with HF
Delivery of CRT guided by non-invasive anatomy assessment
RELIEVE-ing HFrEF with interatrial shunting
Miscellaneous
Algorithm-based remote patient monitoring was associated with lower mortality in a retrospective cohort study
High mortality and morbidity in suspected de novo HF in outpatient care
Bio-ADM as a marker for congestion in patients hospitalised for acute HF
Hypertonic saline not effective in ambulatory patients with heart failure?
No effect of low-dose carperitide on mortality or hospitalisation in acute HF
Trials: Pharmacology
Effects of semaglutide on MACE irrespective of HF status
SEQUOIA-HCM: Aficamten demonstrates clinical efficacy in obstructive HCM
ARIES-HM3 trial: Subgroup analysis in patients with prior need for aspirin
Three diuretic regimens compared in the DEA-HF study
Adding a mineralocorticoid receptor modulator in heart failure with CKD
SGLT2 Inhibitors
Empagliflozin did not reduce mortality for HF after MI regardless of T2D status
SGLT2 inhibitors decrease atrial fibrillation risk in patients with HFrEF
SGLT2 inhibition: Major and early impact on heart failure hospitalisation risk
Related Articles
September 27, 2021
SGLT2i or GLP-1-RA for heart protection in type 2 diabetes?
© 2024 Medicom Medical Publishers. All rights reserved. Terms and Conditions | Privacy Policy
HEAD OFFICE
Laarderhoogtweg 25
1101 EB Amsterdam
The Netherlands
T: +31 85 4012 560
E: publishers@medicom-publishers.com